When was NeuroPace founded?

NeuroPace was founded in 1997 and raised its 1st funding round 6 years after it was founded.

Where is NeuroPace located?

NeuroPace is headquartered in Mountain View, United States. It is registered at Mountain View, California.

How many employees does NeuroPace have?

As of Sep 30, 2026, the latest employee count at NeuroPace is 244.

Is NeuroPace a funded company?

NeuroPace is a funded company, having raised a total of $264M across 9 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 09, 2003.

When was the latest funding round of NeuroPace?

NeuroPace's latest funding was a $***** Grant (prize money) round on Aug 20, 2025, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $4.65B in funding in 2026 to date.

What is the annual revenue of NeuroPace?

Annual revenue of NeuroPace is between $50M and $100M as on Dec 31, 2025

Where does NeuroPace rank among its competitors?

NeuroPace ranks 1st amongst 27 active competitors, of which 5 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was NeuroPace, which secured $9.74M in Aug, 2025.

Who are the top competitors of NeuroPace?

NeuroPace's top competitors include INBRAIN Neuroelectronics, LivaNova and Cadence Neuroscience. Among them, NeuroPace secured the most recent funding round in August, 2025.

NeuroPace - 2026 Company Profile, Funding, Competitors & Financials

NeuroPace is a public company based in Mountain View (United States), founded in 1997. It operates as a Developer of implantable neurostimulation system for epilepsy treatment. NeuroPace has raised $264M in funding from investors like New Enterprise Associates, Technology Partners and InterWest Partners. The company has 27 active competitors, including 5 funded and 6 that have exited. Its top competitors include companies like INBRAIN Neuroelectronics, LivaNova and Cadence Neuroscience.

Company Details

Developer of implantable neurostimulation system for epilepsy treatment. The system delivers personalized treatment by responding to abnormal brain activity and provides EEG data to improve patient care. It offers a potential solution for adults with drug-resistant focal epilepsy, aiming to reduce seizures and manage quality of life. The device is intended for patients with localized seizure foci and requires prior diagnostic testing. The company also provides resources and support for patients and healthcare providers.

Website: neuropace.com
Registered Address: Mountain View, California

Key Metrics

Founded Year

1997

Location

Mountain View, United States

Stage

Public

Total Funding

$264M in 9 rounds

Latest Funding Round

Grant (prize money), Aug 20, 2025, $*****

Investors

New Enterprise Associates & 17 more

Ranked

1^st among 27 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

244 as on Sep 30, 2026

Similar Companies

INBRAIN Neuroelectronics & 29 more

Exit Details

Public

View NeuroPace's full profile

NeuroPace is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
NEUROPACE INC CIN: 1528287 , United States, Active	Aug 29, 2011	$50M - $100M (As on Dec 31, 2025)	-	-
NEUROPACE, INC. CIN: 223550230 , United States, Active	Dec 26, 999	-	185 (As on Dec 31, 2024)	-

NeuroPace got listed on Apr 22, 2021.

Click here to take a look at NeuroPace's IPO in detail

NeuroPace has raised a total funding of $264M over 9 rounds. Its first funding round was on Sep 09, 2003. Its latest funding round was a Grant (prize money) round on Aug 20, 2025 for $*****. 1 investor participated in its latest round. NeuroPace has 18 institutional investors.

Here is the list of recent funding rounds of NeuroPace:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 20, 2025	3478687	Grant (prize money)	3341729	5544260	9633050	9545253
Aug 19, 2020	3449613	Series E	9369149	2968414	4515231	Soleus Capital & 2 more
Sep 21, 2016	7641599	Series E	7902239	6004427	Orbimed & 1 more	3269754

Access funding benchmarks and valuations. Sign up today!

View details of NeuroPace's funding rounds and investors

NeuroPace's employee count trend

NeuroPace has 244 employees as of Sep 26. Here is NeuroPace's employee count trend over the years:

Uncover NeuroPace's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of NeuroPace include INBRAIN Neuroelectronics, LivaNova and Cadence Neuroscience. Here is the list of Top 10 competitors of NeuroPace, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	NeuroPace 1997, Mountain View (United States), Public	Developer of implantable neurostimulation system for epilepsy treatment	$264M	Accelmed, Domain Associates & 16 others	67/100
2nd	INBRAIN Neuroelectronics 2019, Barcelona (Spain), Series B	Developer of implantable neurotechnology for decoding and modulating brain activity	$82.8M	Asabys Partners, Alta Life Sciences & 16 others	67/100
3rd	LivaNova 2015, London (United Kingdom), Public	Provider of cardiac and neurological therapeutic devices	-	Ministry of Economic Development, Lightstone Ventures ... & 4 others	65/100
4th	Cadence Neuroscience 2016, Redmond (United States), Series B	Developer of medical devices for treating neurological disorders	$41M	JAZZ Venture Partners, Angelini Lumira Biosciences Fund ... & 10 others	55/100
5th	Cyberonics 1987, Houston (United States), Public	Vagus nerve stimulation device for epilepsy and treatment resistant depression	-	-	46/100
6th	Engage Therapeutics 2017, Summit (United States), Acquired	Inhaled drug-device combo as rescue treatment for uncontrolled epileptic seizures	$30.6M	Adage Capital Management, Lumira Ventures ... & 5 others	42/100
7th	NeuroVice 2016, Cary (United States), Funding Raised	Developing innovative oral health solutions for seizure-related injuries and improving patient experience	-	-	38/100
8th	NeuroOne 2015, Eden Prairie (United States), Deadpooled	Provider of minimally invasive diagnostics, neuromonitoring and neuromodulation devices	$1.53M	MBX Capital	36/100
9th	Neurolink 2007, San Antonio (United States), Deadpooled	Drug-device combination for epilepsy	$3.88M	InCube Ventures, North Texas RCIC & 1 others	34/100
10th	OceansBIo 2021, Changwon (South Korea), Public	Developer of electroceutical devices for epilepsy treatment	-	STH, Korea Credit Guarantee Fund & 3 others	33/100